roxadustat
Sign in to saveAlso known as ASP-1517, ASP1517, FG-4592, FG4592, HIF prolyl-hydroxylase inhibitor, FG 4592, AZD9941
Roxadustat, sold under the brand name Evrenzo, is an anti-anemia medication. Roxadustat is a HIF prolyl-hydroxylase inhibitor that increases endogenous production of erythropoietin and stimulates production of hemoglobin and red blood cells. It was investigated in clinical trials for the treatment of anemia caused by chronic kidney disease. It is taken by mouth. The drug was developed by FibroGen, in partnership with AstraZeneca.
Wikidata facts
- Mass
- 352.105922
Show 4 more facts
- Commons category
- Roxadustat
- World Health Organisation international non-proprietary name
- roxadustat
- chemical formula
- C₁₉H₁₆N₂O₅
- canonical SMILES
- CC1=NC(=C(C2=C1C=C(C=C2)OC3=CC=CC=C3)O)C(=O)NCC(=O)O
via Wikidata · CC0
~4 min read
Article
8 sectionsContents
- Medical uses
- Adverse effects
- Society and culture
- Legal status
- Usage as a doping product
- Synthesis
- References
- Further reading
Roxadustat, sold under the brand name Evrenzo, is an anti-anemia medication. Roxadustat is a HIF prolyl-hydroxylase inhibitor that increases endogenous production of erythropoietin and stimulates production of hemoglobin and red blood cells. It was investigated in clinical trials for the treatment of anemia caused by chronic kidney disease. It is taken by mouth. The drug was developed by FibroGen, in partnership with AstraZeneca.
The most common side effects include hypertension (high blood pressure), vascular access thrombosis (formation of blood clots in the blood vessels associated with dialysis), diarrhea, peripheral edema (swelling especially of the ankles and feet), hyperkalemia (high blood potassium levels) and nausea (feeling sick).